title: Apolipoprotein B-48 to triglyceride ratio is a novel and useful marker for detection of type III hyperlipidemia after antihyperlipidemic intervention.
abstract: OBJECTIVE
  Remnant lipoproteins are atherogenic and are accumulated in patients with type III hyperlipidemia (HL). Although type III HL is diagnosed by phenotyping apolipoprotein (apo) E, this procedure is time-consuming and inconvenient for routine clinical use. Clinical indices for screening type III HL in untreated HL patients have been proposed; however, in clinical settings, HL patients are promptly treated with lipid-lowering agents without diagnosing the underlying cause. We investigated whether existing clinical indices for screening type III HL as well as the apo B-48/triglyceride (TG) ratio, which was suggested to be related to the accumulation of small chylomicron (CM) remnants, are useful after the initiation of lipid-lowering therapies.
  
  
  METHODS
  In 25 normolipidemic subjects and 191 treated HL patients (type I, n =6; IIa, 62; IIb, 66; III, 12; IV, 22; and V, 23) from Osaka University Hospital and related hospitals, fasting low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), TG, and apolipoproteins were measured and clinical indices were evaluated statistically.
  
  
  RESULTS
  Apo B-48 levels were significantly higher in patients with type I, III, and V HL, and TG levels were significantly higher in patients with type I and V HL. The apo B-48/TG ratio was significantly higher only in patients with type III HL compared with other types of HL (p<0.001), and was statistically significant among the other clinical indices (AUC-ROC value, 0.895; cut-off value, 0.110).
  
  
  CONCLUSIONS
  The apo B-48/TG ratio is a novel and useful marker for detecting type III HL even after the initiation of lipid-lowering interventions.
authors.affiliation: Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Osaka, Japan.
authors.forename: Miyako
authors.initials: M
authors.lastname: Yuasa-Kawase
authors.forename: Daisaku
authors.initials: D
authors.lastname: Masuda
authors.forename: Rika
authors.initials: R
authors.lastname: Kitazume-Taneike
authors.forename: Taiji
authors.initials: T
authors.lastname: Yamashita
authors.forename: Ryota
authors.initials: R
authors.lastname: Kawase
authors.forename: Hajime
authors.initials: H
authors.lastname: Nakaoka
authors.forename: Miwako
authors.initials: M
authors.lastname: Inagaki
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Nakatani
authors.forename: Kazumi
authors.initials: K
authors.lastname: Tsubakio-Yamamoto
authors.forename: Tohru
authors.initials: T
authors.lastname: Ohama
authors.forename: Yumiko
authors.initials: Y
authors.lastname: Toyama-Nakagawa
authors.forename: Makoto
authors.initials: M
authors.lastname: Nishida
authors.forename: Masato
authors.initials: M
authors.lastname: Ishigami
authors.forename: Mieko
authors.initials: M
authors.lastname: Saito
authors.forename: Masaaki
authors.initials: M
authors.lastname: Eto
authors.forename: Akifumi
authors.initials: A
authors.lastname: Matsuyama
authors.forename: Issei
authors.initials: I
authors.lastname: Komuro
authors.forename: Shizuya
authors.initials: S
authors.lastname: Yamashita
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D053283:Apolipoprotein B-48 / Q000097:blood*; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000175:diagnosis* / Q000188:drug therapy; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008074:Lipoproteins / Q000097:blood*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D014280:Triglycerides / Q000097:blood*
chemical_list: D053283:Apolipoprotein B-48; D000960:Hypolipidemic Agents; D008074:Lipoproteins; D014280:Triglycerides